logo-loader
viewRecce Pharmaceuticals Ltd

Recce Pharmaceuticals to talk new class of synthetic antibiotics at Proactive’s CEO Sessions

Five companies will present at Proactive’s CEO Sessions in Sydney on February 3 and Melbourne on February 4.

Recce Pharmaceuticals Ltd - Recce Pharmaceuticals to talk new class of synthetic antibiotics at Proactive’s CEO Sessions
Recce executive director James Graham will talk about the company’s progress and plans

Recce Pharmaceuticals Ltd (ASX:RCE) is pioneering the development and commercialisation of a new class of synthetic antibiotics designed to address the urgent global health problem of antibiotic resistant superbugs.

The company’s antibiotics are unique – their potency does not diminish even with repeated use, which is a common failure associated with existing antibiotic use and the resulting emergence of resistant superbugs.

Recce executive director James Graham will talk about the company’s progress and plans at Proactive’s CEO Sessions in Sydney on February 3 and Melbourne on February 4 along with four other companies.

Fighting antibiotic resistant superbugs

Recce’s patented lead candidate RECCE 327, wholly owned and manufactured in Australia, has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria – including their superbug forms.

The FDA has awarded RECCE 327 Qualified Infectious Disease Product designation under the Generating Antibiotic Initiatives Now (GAIN) Act – labelling it for Fast Track Designation, plus 10 years of market exclusivity post approval.

Efficacy against MRSA superbug

RECCE 327 recently showed significant efficacy against the MRSA superbug in the treatment of burns wound infection in an animal model.

The study was undertaken in co-operation with an established Australian teaching hospital, by an independent contract research organisation.

Top line results showed significant in vivo antibacterial activity against Methicillin-Resistant Staphylococcus aureus (MRSA – superbug) in rats with topical burns: RECCE 327 reduced bacterial load and enhanced wound closure.

A separate human skin model showed the antibiotic was non-irritating, even at high concentrations.

Broad range of clinical treatments

Recce chairman Dr. John Prendergast said at the time of publishing the study results: “These data demonstrate that RECCE antibiotics has great potential to be applied in a broad range of clinical treatment settings.

“With significant data synergies from our lead indication in the treatment of sepsis, to another area of urgent unmet need, these new results support Recce’s potential to address the increasing threat of antibiotic resistant superbugs.”

Five companies presenting

Five companies will present at the Sydney and Melbourne events, including Antisense Therapeutics Limited (ASX:ANP) and Great Boulder Resources Ltd (ASX:GBR).

Register now for the CEO Sessions:

Sydney event, Monday, February 3

Melbourne event, Tuesday, February 4

Quick facts: Recce Pharmaceuticals Ltd

Price: 0.315 AUD

ASX:RCE
Market: ASX
Market Cap: $42.23 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Legend Mining’s proof of concept Fraser Range hole sets the...

Legend Mining Limited (ASX:LEG) managing director Mark Wilson updates Proactive on the company's plans for 2020 after a recent quantum leap in its exploration on WA's prolific Fraser Range. He said that 2019 finished with a bang with a discovery hole at Mawson prospect in the Rockford project...

10 hours, 27 minutes ago

3 min read